An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kansas
• Treatments: Letrozole

Criteria

Inclusion Criteria:

• evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast

• on hormone replacement therapy

• postmenopausal

• increased risk of developing breast cancer based on personal or family history

• never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months

• women who have a high risk of breast cancer

• older than 18 years

Exclusion Criteria:

• no anticoagulants

• no marked breast tenderness

• not pregnant or within twelve months of breast feeding/childbirth